Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma
October 4th 2023Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.
Read More
ADC Technology and Mechanism of Action
July 13th 2022Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.
Read More